Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes
Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.
Inclusion Criteria:
Exclusion Criteria:
Kladno - Krocehlavy, 272 01, Czechia
Kiel Kronshagen, 24119, Germany
Oldenburg I. Holst, 23758, Germany
Pohlheim, 35415, Germany
Saint Ingbert-Oberwürzbach, 66386, Germany
Hyderabad, Andhra Pradesh 500072, India
New Dehli, New Delhi 110029, India
Chandigarh, Punjab 160012, India
Hyderbad, Telangana 500 012, India
Cosmo City, Gauteng 2188, South Africa
Fuenlabrada - Madrid, 28942, Spain